Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update
Matinas Biopharma Holdings’ short interest fell sharply in May, dropping to 387 shares as of May 15 from 4,431 shares on April 30, a 91.3% decrease, according to the report. The stock traded at $0.81 mid-day Friday. DRW Securities LLC bought 46,374 shares in Q4, worth about $27,000, per SEC disclosure.
How this was made
The 30-second read
Why it matters
The main tradable signal is the reported May short-interest collapse, which can affect hedging demand and sentiment. The institutional buy is supportive but is not tied to a new, time-sensitive corporate event in this article.
Market read
Lower reported short exposure can reduce sell pressure and improve sentiment, but the absolute short-interest figures are tiny, so the signal may be noisy.
What to watch
With very low market cap and thin liquidity, short-interest metrics can swing sharply; traders should verify borrow availability, actual short volume, and whether any new catalysts (e.g., trial/data) are present.
Background
The piece is a short-interest update for Matinas Biopharma and also mentions a recent institutional stake purchase (DRW Securities) plus basic trading/MA levels and the last EPS print (May 8).
Ticker impact
Matinas Biopharma’s short interest reportedly collapsed in May, with the article citing 0.0% currently shorted and a sharp drop in shares short.
Mildly bullish near-term bias; any follow-through likely depends on whether liquidity/volume supports a sustained squeeze.
The article provides a large percentage decline in short interest and notes 0.0% shorted, which can mechanically lower borrow/hedge demand; however, the absolute short-interest share counts are extremely small, increasing the risk of noise.
Market effects
Limited read-across to biotech broadly; short-interest dynamics are company-specific and often driven by liquidity/float.
None indicated beyond small-cap US microcap sentiment.
None.
Counterpoint
The reported 0.0% shorted may reflect reporting/coverage changes or very small absolute short positions rather than a true shift in fundamental risk.
Key entities
- issuerMatinas Biopharma Holdings, Inc.
Clinical-stage biopharmaceutical developing lipid-based drug delivery and MAT2203 for fungal infections.
- institutional_investorDRW Securities LLC
Reportedly purchased 46,374 shares in the fourth quarter per SEC disclosure.
